Key result
Appropriate DOAC dosing was observed in 93.6% of VA patients with atrial fibrillation overall, and in 83.2% of those with chronic kidney disease.
Why the study?
Inappropriate DOAC dosing is common, especially in chronic kidney disease, but the prevalence of overdosing and underdosing within VA anticoagulation management programs was unknown.
Population
VA patients with newly diagnosed AF receiving a DOAC between 2003 and 2015
Comparison
Correct vs overdosed vs underdosed DOAC regimens
Design
Retrospective cohort study
Authors
Loading...
Inappropriate DOAC dosing in CKD may persist despite VA programs; leaves open impact on outcomes and need for prospective trials.
Cohort
Yes
In a VA cohort where DOAC management is often pharmacist-led, the vast majority of patients with atrial fibrillation received appropriate DOAC dosing, suggesting structured management programs may reduce incorrect dosing.
Leef et al. (2019) conducted a cohort in Atrial Fibrillation. Direct oral anticoagulants (DOACs) was evaluated on Appropriate DOAC dosing based on FDA-approved criteria. Appropriate DOAC dosing was observed in 93.6% of VA patients with atrial fibrillation overall, and in 83.2% of those with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: